E17 exerts anti-tumor activity through inhibiting topo II-mediated chromosomes condensation in CRC cells

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Topoisomerase II (Topo II) inhibitors like etoposide are crucial in cancer therapy.
• These drugs function by trapping the Topo II-DNA complex, leading to DNA damage and multidrug resistance (MDR).
• Identifying novel Topo II inhibitors with improved efficacy and reduced side effects is essential.

Purpose of the Study:

• To investigate the inhibitory activity and mechanism of a newly identified Topo II inhibitor, designated E17.
• To evaluate E17's effects on colorectal cancer (CRC) HCT116 cells, focusing on cell viability, cycle, and DNA integrity.
• To compare E17's mechanism with existing Topo II inhibitors like VP16 and ICRF-187.

Main Methods:

• Cell viability, colony formation, and migration assays were performed using HCT116 cells.
• Cell cycle progression was analyzed to determine the effect of E17 on cell cycle arrest.
• Topo II-DNA complex formation and Topo II degradation were assessed to elucidate the drug's mechanism of action.

Main Results:

• E17 demonstrated potent inhibition of HCT116 cell viability, colony formation, and migration.
• E17 induced G2/M cell cycle arrest by inhibiting chromosome condensation, notably without causing significant DNA damage.
• E17 treatment led to the accumulation of Topo II-DNA complexes but did not induce Topo II degradation, distinguishing it from VP16 and ICRF-187.

Conclusions:

• E17 exhibits strong Topo II inhibitory activity and unique mechanisms of action in colorectal cancer cells.
• Its ability to induce cell cycle arrest without substantial DNA damage suggests a potentially favorable therapeutic profile.
• E17 represents a promising lead compound for the development of novel anti-cancer therapeutics targeting Topo II.